Anti-Angiogenic Tyrosine Kinase Inhibitors and Reversible Posterior Leukoencephalopathy Syndrome: Could Hypomagnesaemia Be the Trigger?
Reversible posterior leukoencephalopathy syndrome (RPLS), also known frequently as posterior reversible encephalopathy syndrome (PRES), is a characteristic acute neuro-radiology syndrome with clinical presentation that typically includes acute hypertension, seizures and other neurological symptoms and signs. Many patients with RPLS have (a history of) pre-existing hypertension and in receipt of diuretics. It is being diagnosed more frequently and in association with an increasing number of morbidities and medications. Drugs most frequently implicated are immunosuppressant drugs and anticancer agents, including a number of anti-angiogenic tyrosine kinase inhibitors (TKIs). Hypomagnesaemia is a frequent finding at presentation in RPLS patients, which is known to lead to or aggravate hypertension. Pre-eclampsia, a variant of RPLS, responds effectively to intravenous magnesium. Cyclosporin, tacrolimus and some TKIs that induce RPLS are also known to give rise to both hypertension and hypomagnesaemia. This raises an interesting hypothesis that hypomagnesaemia may play a contributory role in triggering RPLS in some patients by acutely raising the blood pressure further. Additional systematic studies are required to test this hypothesis. If the hypothesis is confirmed, hypomagnesaemia offers an effective target for risk mitigation and prevention of RPLS in patients identified at risk.
Pharmaceutical Consultant, 8 Birchdale, Gerrards Cross, Buckinghamshire, UK. clinical.safety@hotmail.co.uk.
Rashmi R
RR
Shah
D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000150:complications; D008274:Magnesium / Q000097:blood*; D008275:Magnesium Deficiency / Q000150:complications; D054038:Posterior Leukoencephalopathy Syndrome / Q000139:chemically induced* / Q000209:etiology / Q000503:physiopathology; D047428:Protein Kinase Inhibitors / Q000009:adverse effects; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D012307:Risk Factors; D012308:Risk Management / Q000379:methods
D020533:Angiogenesis Inhibitors; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases; D008274:Magnesium